Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence회복기 동안 경증 COVID-19 외래 환자의 지속적인 항체 의존성 NK 세포 기능Immunology Published on 2022-02-072022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome addition Anti-spike anti-spike antibody anti-viral response antibody blood sample Cell characterized Cohort collected contribute convalescence coronavirus coronavirus disease correlated COVID-19 COVID-19 outpatients COVID19 defined disease Fc-effector functions female function heterogeneous humoral Humoral response identify IgA IgG titers immune correlate male natural killer neutralization NK cells activity Outpatient outpatients pandemic profile researcher response responses SARS-CoV-2 severity spike (S) glycoprotein Spike protein sustained the SARS-CoV-2 Virus neutralization while [DOI] 10.3389/fimmu.2022.796481 PMC 바로가기 [Article Type] Immunology
Characterising within-hospital SARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves두 가지 유행성 파동에 걸친 역학 및 바이러스 게놈 데이터를 사용하여 병원 내 SARS-CoV-2 전파 이벤트 특성화Article Published on 2022-02-032022-09-10 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, [키워드] Bayesian Control COVID19 Disruption epidemiological epidemiological data Epidemiology event genomic genomic data Genomics healthcare service healthcare services healthcare worker Healthcare workers hospital hospitals infections introduced measure Mortality NHS nosocomial onward transmission outbreak pandemic Patient Prevent reduced required SARS-CoV-2 SARS-CoV-2 transmission Sequencing Transmission transmissions Trust Viral Wave whole genome Whole genome sequencing [DOI] 10.1038/s41467-022-28291-y PMC 바로가기 [Article Type] Article
Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cellResearch Article Published on 2022-02-022022-10-04 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 229E acute respiratory syndrome addition antibiotic Antiviral antiviral activity binding brilacidin Cell culture cell cultures cell entry clinical trial combination therapy coronavirus COVID‐19 COVID19 Defense drug drug candidate heparin Host host cell host cell surface HSPGs human coronavirus inhibit inhibitory activity mechanism mechanism of action multiple cell line multiple cell lines NL63 OC43 peptide Phase 2 Proteoglycan provide pseudovirus Remdesivir reported SARS‐CoV‐2 SARS‐CoV‐2 synergistic translational virucidal virus [DOI] 10.1002/jmv.27616 PMC 바로가기 [Article Type] Research Article
Respiratory and peripheral muscular ultrasound characteristics in ICU COVID 19 ARDS patientsICU COVID 19 ARDS 환자의 호흡기 및 말초 근육 초음파 특성Observational Study Published on 2022-02-012022-09-11 Journal: Journal of critical care [Category] COVID19(2023년), SARS, 임상, 치료기술, [키워드] Admission affected ARDS ARDS patient benefit change Characteristics clinically coronavirus disease Coronavirus disease 2019 correlation COVID 19 COVID19 cross-sectional area cumulative dead patients develop Diaphragm diaphragmatic echogenicity Fluid balance Grayscale Grayscale analysis ICU intubated patient material mechanical ventilation muscle muscles muscular Muscular ultrasound. observational study parasternal Patient performed prospective observational study Protein reduce respiratory severe cases significantly significantly lower survived therapy thickness Ultrasound Urine [DOI] 10.1016/j.jcrc.2021.09.007 PMC 바로가기 [Article Type] Observational Study
Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro StudyArticle Published on 2022-02-012023-07-06 Journal: Molecular informatics [Category] COVID19(2023년), [키워드] COVID19 docking Drug repurposing main protease MD simulations SARS-CoV-2 Spike/ACE-2 Virtual screening [DOI] 10.1002/minf.202100062 PMC 바로가기
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysisCOVID19 전염병 동안 18개월 동안 대량 사용 후 SARS-COV-2 게놈에서 매우 낮은 수준의 렘데시비르 내성: GISAID 탐색 분석Article Published on 2022-02-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] Analysis Antiviral Antiviral compound Antiviral compounds controlled trials COVID-19 COVID19 E802D Efficacy effort Emergency use authorization Exploratory analysis fitness Frequency Genome GISAID GISAID database hospitalized patients In vitro studies in vivo inhibitor massive molnupiravir mutations Nsp12 pandemic Randomized controlled trial Randomized controlled trials RdRP RdRp mutation RdRp mutations Remdesivir resistance reveal RNA RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 sequencing Strains Viral RNA viral RNA-dependent RNA polymerase [DOI] 10.1016/j.antiviral.2022.105247 PMC 바로가기 [Article Type] Article
Cholecystectomies in the COVID-19 Pandemic During and After the First Lockdown in Germany: an Analysis of 8561 PatientsArticle Published on 2022-02-012023-07-06 Journal: Journal of Gastrointestinal Surgery [Category] COVID19(2023년), [키워드] Cholecystectomie COVID19 lockdown [DOI] 10.1007/s11605-021-05157-0 PMC 바로가기
Trauma workload during COVID19 lockdown: an analysis of incidence in 4 million peopleArticle Published on 2022-02-012023-07-06 Journal: Irish Journal of Medical Science [Category] COVID19(2023년), [키워드] COVID19 Fracture Injury lockdown trauma [DOI] 10.1007/s11845-021-02548-9 PMC 바로가기
COVID 19 and the risk of gastro-intestinal perforation: A case series and literature reviewReview Published on 2022-02-012023-07-07 Journal: Journal of critical care [Category] COVID19(2023년), [키워드] Complication COVID19 Gastro-intestinal perforation IL-6 inhibition. [DOI] 10.1016/j.jcrc.2021.10.020 PMC 바로가기 [Article Type] Review
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and PharmacodynamicsCOVID 폐렴에서 정맥내 나파모스타트 메실레이트의 무작위 대조 시험: 안전성, 약동학 및 약력학을 조사하기 위한 1b/2a상 실험 연구Clinical Trial Published on 2022-02-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 신약개발, 임상, 치료제, [키워드] 95% CI Administered adverse events Analysis Anti-inflammatory Anticoagulant anticoagulant effect anticoagulant effects antiviral activity assigned average characterisation Controlled trial COVID COVID-19 COVID19 creatinine credible interval demonstrated dose Edinburgh Endpoint endpoints Evidence evidence of Hospital stay hospitalised hospitalised patient Hospitalised patients inactive independent Infectious diseases intravenous intravenous infusion manuscript maximum mean difference mesylate metabolites nafamostat Nafamostat mesylate observé Odds ratio open open label Oxford oxygen Patient patients Pharmacodynamics pharmacokinetics phase Phase 2 PK data plasma platform Pneumonitis Primary outcome Primary outcomes progressed randomised randomised controlled trial Randomly rate ratio receive reported Repurposed drug Research respiratory Respiratory medicine response SARS-CoV-2/COVID-19 Seven significantly higher significantly more SOC Standard of care statistically significant difference therapy Tolerability Total Total manuscript word count. Trial university with COVID-19 [DOI] 10.1016/j.ebiom.2022.103856 PMC 바로가기 [Article Type] Clinical Trial